60 Degrees Pharma (SXTP) secured an exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease pipeline. While no financial terms or clinical milestones were provided, the deal adds a potentially material biotech asset and supports a modest positive outlook for future development opportunities.
60 Degrees Pharma (SXTP) secured an exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease pipeline. While no financial terms or clinical milestones were provided, the deal adds a potentially material biotech asset and supports a modest positive outlook for future development opportunities.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
